Zydus Lifesciences secures USFDA EIR for Jarod injectable facility

Zydus Lifesciences Limited has confirmed the receipt of an Establishment Inspection Report (EIR) from the USFDA for its injectable facility located in Jarod, Vadodara. The inspection, conducted from August 25 to September 5, 2025, resulted in the facility being classified as Voluntary Action Indicated (VAI).

This GMP follow-up inspection comes after a Warning Letter was issued by the USFDA on August 29, 2024. The receipt of the EIR signifies a significant regulatory development for the company's manufacturing operations.

The company stated that this disclosure is made in accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.